Evidence map›Paper›PMID 35203955›Full record

ReviewBrain sciences2022

Biomarkers in Neuropsychiatric Systemic Lupus Erythematosus: A Systematic Literature Review of the Last Decade.

Julius Lindblom, Chandra Mohan, Ioannis Parodis

Open access · goldAbstract readReview
In one paragraph

Review in Brain sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 3 pooled it
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 3 syntheses or guidelines pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Blood-Brain Barrier Disruption in Neuroimmunological Disease.International journal of molecular sciences · 2024
    Review
  15. Immune Mechanisms and Biomarkers in Systemic Lupus Erythematosus.International journal of molecular sciences · 2024
    Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Julius LindblomDivision of Rheumatology, Department of Medicine Solna, Karolinska Institute and Karolinska University Hospital, 17176 Stockholm, Sweden.ORCID 0000-0003-1582-9471
Chandra MohanDepartment Biomedical Engineering, University of Houston, Houston, TX 77204, USA.
Ioannis ParodisDivision of Rheumatology, Department of Medicine Solna, Karolinska Institute and Karolinska University Hospital, 17176 Stockholm, Sweden.ORCID 0000-0002-4875-5395
Karolinska University Hospital · SEUniversity of Houston · US

Funding

Monitoring Disease in LupusR01AR074096 · NIAMS · UNIVERSITY OF HOUSTON · PI CHANDRA MOHAN · 2019 to 2026
$4.5M
Karolinska InstituteKing Gustaf V's 80-year Foundation FAI-2020-0741Lupus Research AllianceNIH HHS R01 AR074096Professor Nanna Svartz Foundation 2020-00368Stockholm County Council FoUI-955483Swedish Rheumatism Association R-941095Ulla and Roland Gustafsson Foundation 2021-26
6 · The paper itself

Abstract

Nervous system involvement in patients with SLE, termed neuropsychiatric SLE (NPSLE), constitutes a diagnostic challenge, and its management is still poorly optimised. This review summarises recent insights over the past decade in laboratory biomarkers of diagnosis, monitoring, and prognosis of NPSLE. An initial systematic search in the Medline and Web of Science was conducted to guide the selection of articles. Emerging diagnostic biomarkers in NPSLE that displayed satisfactory ability to discriminate between NPSLE and controls include serum interleukin (IL)-6, microRNA (miR)-23a, miR-155, and cerebrospinal fluid (CSF) α-Klotho. CSF lipocalin-2, macrophage colony-stimulating factor (M-CSF), and immunoglobulin (Ig)M also displayed such ability in two ethnically diverse cohorts. Serum interferon (IFN)-α and neuron specific enolase (NSE) were recently reported to moderately correlate with disease activity in patients with active NPSLE. CSF IL-8, IL-13, and granulocyte colony-stimulating factor (G-CSF) exhibited excellent sensitivity, yet poorer specificity, as predictors of response to therapy in patients with NPSLE. The overall lack of validation studies across multiple and diverse cohorts necessitates further and well-concerted investigations. Nevertheless, we propound CSF lipocalin 2 among molecules that hold promise as reliable diagnostic biomarkers in NPSLE.

Indexed as

biomarkersdiagnosismonitoringneuropsychiatric systemic lupus erythematosusprognosissystemic lupus erythematosus

Identifiers

PMID35203955
PMCPMC8869794
OpenAlexW4210435144

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.